Immatics (IMTX) EBITDA Margin (2019 - 2026)
Immatics (IMTX) posted EBITDA Margin of 1.82% for Q4 2025, up 99.82% sequentially from 982.48% in Q3 2025, and down 7833.0% YoY from 0.02% in Q4 2024.
Powered by 
Analysis
Immatics (IMTX) EBITDA Margin (2019 - 2026) Analysis & Trends
Immatics has reported EBITDA Margin for 7 years, with the latest figure at 1.82% in Q4 2025.
- Quarterly EBITDA Margin fell 7833.0% year-over-year to 1.82% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 318.62% (down 32341.0% YoY) and the FY2025 annual result came in at 377.11%, down 35233.0% from the prior year.
- EBITDA Margin grew to 1.82% in Q4 2025 per IMTX's latest filing, from 982.48% in the prior quarter.
- Over five years, EBITDA Margin peaked at 82.16% in Q1 2022 and troughed at 1025.4% in Q2 2025.
- A 5-year average of 242.76% and a median of 116.92% in 2023 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2021 and 2025: EBITDA Margin jumped 174351 bps in 2021, then plunged 95292 bps in 2025.
- Over 5 years, EBITDA Margin stood at 108.81% in 2021, then jumped by 59 bps to 44.47% in 2022, then tumbled by 167 bps to 118.63% in 2023, then jumped by 164 bps to 76.51% in 2024, then slumped by 102 bps to 1.82% in 2025.
- According to Business Quant data, EBITDA Margin over the past three periods registered 1.82%, 982.48%, and 1025.4% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - | -734.95% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -734.95% |
| Mar 31, 2026 | -867.89% |
| Dec 31, 2025 | -196.76% |
| Sep 30, 2025 | -1,053.27% |
| Jun 30, 2025 | -1,121.53% |
| Mar 31, 2025 | -190.37% |
| Dec 31, 2024 | 1.61% |
| Sep 30, 2024 | 1.02% |
| Jun 30, 2024 | -141.64% |
| Mar 31, 2024 | -44.50% |
| Dec 31, 2023 | -174.07% |
| Sep 30, 2023 | -561.37% |
| Jun 30, 2023 | -64.04% |
| Mar 31, 2023 | -269.80% |
| Dec 31, 2022 | 0.12% |
| Sep 30, 2022 | -145.58% |
| Jun 30, 2022 | -96.76% |
| Mar 31, 2022 | 66.56% |
| Dec 31, 2021 | -102.12% |
| Sep 30, 2021 | -356.99% |